deltatrials
Terminated PHASE1 INTERVENTIONAL 3-arm NCT03238651

A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)

A Phase 1, Open-label Study of TAK-659 as a Single Agent in Adult East Asian Patients With Non-Hodgkin Lymphoma

Sponsor: Calithera Biosciences, Inc

Conditions Lymphoma, Follicular, Marginal Zone Lymphoma, Non-Hodgkin
Interventions TAK-659
Updated 15 times since 2017 Last updated: Feb 6, 2023 Started: Aug 1, 2017 Primary completion: Aug 17, 2020 Completion: Aug 17, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Termination of the study by the sponsor due to business decision.

Other terminated trials from Calithera Biosciences, Inc

More terminations from Calithera Biosciences, Inc

A PHASE1 clinical study on Lymphoma, Follicular, Marginal Zone and Lymphoma, Non-Hodgkin, this trial is terminated or withdrawn. The trial is conducted by Calithera Biosciences, Inc and has accumulated 15 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Mar 2019 · 5 months · monthly snapshot~Mar 2019 – ~Jan 2020 · 10 months · monthly snapshot~Jan 2020 – ~May 2020 · 4 months · monthly snapshot~May 2020 – ~Oct 2020 · 5 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Mar 2023 · 17 months · monthly snapshot~Mar 2023 – ~Jul 2024 · 16 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  4. Mar 2023 — Jul 2024 [monthly]

    Terminated PHASE1

  5. Oct 2021 — Mar 2023 [monthly]

    Terminated PHASE1

    Status: Completed → Terminated

▶ Show 10 earlier versions

  1. Jan 2021 — Oct 2021 [monthly]

    Completed PHASE1

  2. Oct 2020 — Jan 2021 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  3. May 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE1

  4. Jan 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  5. Mar 2019 — Jan 2020 [monthly]

    Recruiting PHASE1

  6. Oct 2018 — Mar 2019 [monthly]

    Recruiting PHASE1

  7. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE1

  8. Oct 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  9. Sep 2017 — Oct 2017 [monthly]

    Not Yet Recruiting PHASE1

  10. Aug 2017 — Sep 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Calithera Biosciences, Inc
Data source: Calithera Biosciences, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations